Boehringer Ingelheim has recently published a clinical trial data on Spiolto Respimat at ERS Congress in Amsterdam. Prof Dave Singh, Clinical Pharmacology and Respiratory Medicine, University of Manchester, informs Usha Sharma about the benefits and effectiveness of Spiolto Respimat
Recently, Spiolto Respimat’s data was presented at ERS Congress in Amsterdam. Can you reveal more about the findings of the study?
The OTEMTO study shows a greater impact on the quality of life for Spiolto compared to tiotropium. Tiotropium is a good medicine that has successfully treated chronic obstructive pulmonary disease (COPD) patients for many years. OTEMTO shows that lung function and health status are better with spiolto.
How severe is the COPD problem globally?
COPD is projected to be the third biggest cause of death worldwide. The burden of disability is enormous. Spiolto has the potential to significantly improve the lives of many COPD patients in many countries.
The study claims that it works effectively against placebo. Throw some light on the same.
OTEMTO shows that Spiolto has a greater impact on lung function and quality of life compared to tiotropium and compared to placebo.
The study also indicates that it will work effectively and significantly in improving breathless issues and how?
Improving lung function allows patients to breathe more easily, and also to perform their routine daily activities. Spiolto will allow patients to lead a more normal life.
What are the side effects of Spiolto and what precautions do you recommend?
Spiolto many cause mild sde effects such as dry mouth, or urine retention. These resolve on stopping the medicine.
How will these products enhance patients’ quality of life?
Improving lung function allows patients to breathe more easily and also to perform their routine daily activities. Spiolto will allow patients to lead a more normal life.